- Reaction score
- 1,032
In order to get FDA approval the safety profile of a drug is taken into account, a company cannot simply get approval for something if the FDA deems it to be unsafe.
And a drug being approved overseas does not guarantee it can be approved in the U.S.
They must have weighed the potential profits of dutasteride as dralex said, and since propecia did do relatively poorly they chose not to advance it since it would have been a competitor. i would guess they assumed it might command 15% of the Propecia market, and that is not enough for a large pharma company these days. Even small pharma would hesitate when you consider the costs and potential legal issues.
The last numbers I saw for propecia is $150 million per year now, 15% of that is only $22 million. That might not even cover a phase 3 trial, so I doubt it ever goes to phase 3. of coarse generics are out so it might be higher, but the generics today would also be competitors already. It seems dead on arrival now.
What do you mean poorly ? did you saw the numbers ? in 2008 , eleven years after their approve they sell 428 millons dollars of propecia ! They are still marketing and sell it ! a drug that wast on the market 21 years old . You seriously need to learn what profit is.
Why anybody will pass from propecia to avodart is they did the phase 3 ? well, it give the 2.5mg 40 % more hair than 5 mg of finasteride , see the graphic I posted . It have an extremly high life, meaning they can even lunch one pill per week treatment ! Dutasteride should destroid the Propecia, should take all their sales cause is far, far better than finasteride.
Whey they did not ? Check the lawsuit against Merck for propecia and you will understand.
They are selling a product to inhibit and hormone without the indication to even measure them !!!!! That is simple insane.